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Background: Empirical antibiotic therapy is based on patients’ characteristics and antimicrobial
susceptibility data. Hospital-wide cumulative antibiograms may not sufficiently support informed
decision-making for optimal treatment of hospitalized patients.
Methods: We studied different approaches to analysing antimicrobial susceptibility rates (SRs) of all
diagnostic bacterial isolates collected from patients hospitalized between July 2005 and June 2007 at
the University Hospital in Zurich, Switzerland. We compared stratification for unit-specific, specimen
type-specific (blood, urinary, respiratory versus all specimens) and isolate sequence-specific (first,
follow-up versus all isolates) data with hospital-wide cumulative antibiograms, and studied changes of
mean SR during the course of hospitalization.
Results: A total of 16 281 isolates (7965 first, 1201 follow-up and 7115 repeat isolates) were tested. We
found relevant differences in SRs across different hospital departments. Mean SRs of Escherichia coli
to ciprofloxacin ranged between 64.5% and 95.1% in various departments, and mean SRs of
Pseudomonas aeruginosa to imipenem and meropenem ranged from 54.2% to 100% and 80.4% to
100%, respectively. Compared with hospital cumulative antibiograms, lower SRs were observed in
intensive care unit specimens, follow-up isolates and isolates causing nosocomial infections (except
for Staphylococcus aureus). Decreasing SRs were observed in first isolates of coagulase-negative
staphylococci with increasing interval between hospital admission and specimen collection. Isolates
from different anatomical sites showed variations in SRs.
Conclusions: We recommend the reporting of unit-specific rather than hospital-wide cumulative
antibiograms. Decreasing antimicrobial susceptibility during hospitalization and variations in SRs in
isolates from different anatomical sites should be taken into account when selecting empirical
antibiotic treatment.
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Introduction
Antibiotic resistance rates vary widely between countries,1 – 3
within countries4 and between as well as within healthcare insti-
tutions.5 The worldwide emergence of antibiotic resistance due
to increased and inappropriate antibiotic use reduces the treat-
ment options and the overall efficacy of antimicrobials.2,6 In
patients with presumed acute infection, initial empirical
antibiotic therapy, before the results of pathogen identification
and susceptibility testing are available, is selected based on
individual patient characteristics, clinical differential diagnosis,
place of infection (i.e. community versus hospital-acquired) and
non-patient-related epidemiological data such as local bacterial
susceptibility rates (SRs).5,7 The choice of empirical antibacter-
ial therapy in hospitalized patients is guided by institution-
specific cumulative antibiogram reports, which compile mean
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SRs of bacterial isolates collected from other patients previously
treated at the same institution.
Guidelines for the analysis and preparation of cumulative
antibiograms in hospitals have recently been updated.8 They
recommend to only include the first isolate per episode of a
patient’s infection in order to reduce potential overestimation of
antimicrobial resistance due to multiple specimens from the
same patient. However, it may not be adequate to base empirical
antibiotic therapy for individual patients on hospital-wide
overall SRs.5 Incorrect initial empirical treatment may affect
outcome, particularly in critically ill patients.9,10
In order to support guidelines for empirical antibiotic therapy
at our institution, we aimed to compare the hospital-wide cumu-
lative antibiograms of inpatients with the results of additional
subanalyses of susceptibility data. In particular, we stratified
hospital unit-specific versus hospital-wide SRs, anatomical site-
specific (blood, urinary, respiratory versus all specimens), isolate
sequence-specific (first, follow-up versus all isolates) and
hospitalization phase-specific (considering the time between
admission and specimen collection) susceptibility data.
Materials and methods
Setting
The University Hospital in Zurich, Switzerland, is an 860 bed ter-
tiary care teaching hospital. It covers all medical specialties except
paediatrics and orthopaedics. Six intensive care units (ICUs)
(medical ICU, general, thoracic and transplant surgery ICU, trauma
ICU, burn ICU, cardiac surgery ICU, neurosurgery ICU) with a
total of 59 beds are assigned to different departments. Bone marrow
transplantations are performed in a specialized unit.
Data collection
Antimicrobial SRs were assessed and recorded during routine clini-
cal patient care for all diagnostic bacterial isolates obtained from
inpatients hospitalized in ICUs and general wards between 1 July
2005 and 30 June 2007 and were analysed retrospectively. For com-
parisons of nosocomial and community-acquired isolates, isolates
from patients spending .24 h in the emergency unit, its observation
ward or surgical observation wards were also included. Screening
isolates (for example, samples that were analysed at our Hospital
Epidemiology Department in order to assess the need for ongoing
isolation measures in patients who had previously been identified as
carriers of methicillin-resistant Staphylococcus aureus (MRSA) and
extended-spectrum b-lactamase-producing Enterobacteriaceae) were
excluded. All specimens were tested in a central clinical micro-
biology laboratory (Institute of Medical Microbiology, University of
Zurich, Zurich, Switzerland). Bacteria were isolated from blood
cultures and other materials according to standard methods.11
Susceptibility testing of bacterial isolates was performed by the disc
diffusion method; zone diameters were interpreted according to the
CLSI (formerly the NCCLS) guidelines.11 Intermediate suscepti-
bility was categorized as non-susceptible.
The isolates were categorized by the patient’s unit of hospitaliz-
ation at the time of specimen collection, the anatomical site of
specimen recovery (blood culture, urinary, respiratory or other) and
the year of collection. Unless specified otherwise, SRs of first
isolates are reported according to the recently published CLSI
guidelines.8 The problem of handling different phenotypes with
different resistance patterns of an isolate has not been addressed in
these guidelines. Hence, we counted one organism if an isolate
revealed two or more phenotypes of the same organism. However,
we included all phenotypes if they showed different resistance pat-
terns. As a result, the number of susceptibility testing results
exceeds the total number of organisms. Recovery of a minimum of
30 isolates per each hospital unit or anatomical site of infection was
required to be included in the analysis, as recommended.8
Among the repeat isolates, we analysed the first follow-up
isolates in two groups, which were defined a priori, these groups
were ‘early’ follow-up isolates collected between days 0 and 2
after the first isolate, and ‘late’ follow-up isolates collected .2 or
10 days after the first isolate.
Nosocomial isolates were defined as isolates that were collected
more than 48 h after hospital admission and ,30 days after
discharge (in case of readmission) or, in case of missing date of
specimen collection, if they arrived at the Institute of Medical
Microbiology more than 72 h after hospital admission.
Respiratory isolates were defined as isolates recovered from tra-
cheal aspirates, bronchial aspirates or broncho-alveolar lavage. No
assessments against other confounders were made when analysing
data on pathogen susceptibility from different anatomical locations.
Antimicrobial SRs of all bacterial isolates were determined,
but we limit our report to the analyses of Escherichia coli,
Pseudomonas aeruginosa, S. aureus and coagulase-negative staphylo-
cocci, as these organisms were isolated most frequently, accounting
for 28% of all first isolates.
Statistical analyses
We used Stata (Version 9.2, StataCorp, College Station, TX, USA) for
statistical analyses. Fisher’s exact test was used in the analysis of cate-
gorical data. Exact 95% confidence intervals for binomial variables
were calculated. No adjustments for multiple testing were made.
A two-tailed P value of ,0.05 was considered to be statistically
significant.
Results
A total of 16 281 diagnostic bacterial isolates from hospitalized
patients were tested during the 2 year study period. Among
these, 7965 were first, 1201 were follow-up isolates (according
to our definition) and 7115 were other repeat isolates.
Unit-specific versus hospital-wide cumulative antibiograms
Table 1 displays the range of hospital-unit-specific SRs, i.e. the
mean rates of the unit with the lowest and the unit with the
highest SR, in comparison with the mean hospital-wide cumulat-
ive SR of first isolates of E. coli, P. aeruginosa, S. aureus and
coagulase-negative staphylococci. Figure 1 depicts the mean
SRs of E. coli in each single ICU and ward.
We detected significant differences in the overall SRs of
E. coli and P. aeruginosa between departments, i.e. for E. coli
tested against ampicillin, amoxicillin/clavulanic acid, piperacillin/
tazobactam, ciprofloxacin and trimethoprim/sulfamethoxazole; for
P. aeruginosa tested against ceftriaxone, imipenem, meropenem,
piperacillin/tazobactam and tetracycline; and for coagulase-
negative staphylococci tested against ampicillin, oxacillin,
aminoglycosides, trimethoprim/sulfamethoxazole, ciprofloxacin,
erythromycin, clindamycin and rifampicin. For S. aureus isolates,
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significant differences across departments were only detected for
penicillin resistance rates.
The most striking and clinically relevant variations in SRs
between departments were:
† mean E. coli SR to amoxicillin/clavulanic acid, ranging from
62.5% (thoracic and transplant surgery ICU) to 92.7%
(department of neurosurgery);
† mean E. coli SR to ciprofloxacin, ranging from 64.5% (depart-
ment of dermatology) to 95.1% (department of neurosurgery);
† mean E. coli SR to trimethoprim/sulfamethoxazole, ranging
from 58.1% (department of rheumatology) to 86.1% (depart-
ment of neurology);
† mean P. aeruginosa SR to piperacillin/tazobactam, ranging
from 85.0% (medical ICU) to 100% (departments of derma-
tology and gynaecology and obstetrics);
† mean P. aeruginosa SR to imipenem and meropenem,
ranging from 54.2% (thoracic and transplant surgery ICU)
to 100% (department of gynaecology and obstetrics) and
from 80.4 (thoracic and transplant surgery ICU) to 100%
(department of gynaecology and obstetrics), respectively;
† mean P. aeruginosa SR to ciprofloxacin, ranging from 80.0
(medical ICU) to 95.2% (trauma ICU).
ICUs versus general wards
Figure 2 contrasts the SRs of first isolates of E. coli and
P. aeruginosa recovered from ICUs (E. coli, n ¼ 333,
P. aeruginosa, n ¼ 290) and general wards (E. coli, n ¼ 993,
P. aeruginosa, n ¼ 277). The proportion of isolates of
P. aeruginosa susceptible to imipenem (SR 67.97% and 90.14%,
respectively, P, 0.001) and meropenem (SR 89.56% and
95.67%, respectively, P ¼ 0.004) was significantly lower in ICUs
than in general wards. In contrast, general wards had significantly
higher rates of ciprofloxacin-resistant E. coli than ICUs
(SR 81.64% and 90.39%, respectively, P, 0.001).
First versus follow-up versus all isolates
Figure 3 compares the cumulative antibiograms of first versus
follow-up isolates obtained between days 0–2 and 3–10 after
Table 1. Hospital-wide antibiograms and range of unit-specific SRs of the departments with the lowest and the highest rates
Mean susceptibility rates (% of isolates)
E. coli (n ¼ 1326) P. aeruginosa (n ¼ 567)
hospital-wide lowest highest hospital-wide lowest highest
Ampicillin 52.2 40.0 69.4 0.0 0 0
Amoxicillin/clavulanic acid 82.6 62.5 92.7 0.5 0.0 3.3
Piperacillin/tazobactam 97.3 87.5 100 94.6 85.0 100
First-generation cephalosporin 78.5 71.7 96.8 0.2 0.0 1.4
Cefuroxime 90.3 83.7 95.8 1.0 0.0 4.1
Ceftriaxone 97.4 94.1 100 11.8 0.0 22.7
Ceftazidime 97.0 92.5 100 93.4 89.7 100
Cefepime 97.5 97.0 100 92.9 87.2 96.2
Imipenem 100.0 100 100 78.6 54.2 100
Meropenem 100.0 100 100 92.5 80.4 100
Tobramycin 93.4 85.7 98.4 95.8 92.6 100
Trimethoprim/sulfamethoxazole 70.2 58.1 86.1 3.7 0.0 11.1
Ciprofloxacin 83.8 64.5 95.1 88.5 80.0 95.2
Tetracycline 66.2 61.6 82.1 5.5 0.0 16.7
S. aureus (n ¼ 1231) coagulase-negative staphylococci (n ¼ 1430)
Amoxicillin/clavulanic acid 96.3 92.9 100
Ampicillin 24.0 20.5 31.0 15.7 0.0 24.0
Oxacillin 96.3 92.9 100 41.0 12.8 60.0
Amikacin 99.3 97.5 100 86.9 53.1 98.6
Gentamicin 98.4 96.2 100 67.3 12.8 73.1
Tobramycin 96.7 94.5 100 56.5 8.3 77.1
Trimethoprim/sulfamethoxazole 98.9 97.0 100 58.0 10.6 76.0
Ciprofloxacin 93.1 87.5 100 48.4 8.7 93.1
Erythromycin 92.3 88.6 95.1 41.3 17.0 57.6
Clindamycin 98.2 95.8 100 65.7 53.1 96.6
Rifampicin 99.6 97.4 100 84.5 72.9 96.9
Vancomycin/teicoplanin 100 100 100 99.3 97.3 100
Analyses of cumulative antibiograms
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the first isolate, respectively, versus all isolates of E. coli and
P. aeruginosa.
First isolates of E. coli (n ¼ 1326) and P. aeruginosa (n ¼ 567)
were significantly more susceptible to various antibiotics than
follow-up isolates [E. coli, n ¼ 221 (‘early’ follow-up isolates) and
n ¼ 180 (‘late’ follow-up isolates), respectively, P. aeruginosa,
n ¼ 163 (‘early’ follow-up isolates) and n ¼ 165 (‘late’ follow-up
isolates), respectively, or all isolates (E. coli, n¼ 2491;
P. aeruginosa, n¼ 1768)]. Except for the SR of E. coli tested
against ampicillin [SR 30.98% (‘late’ follow-up isolates) and
40.97% (all isolates), respectively, P¼ 0.013], no significant differ-
ences in SRs were detected between ‘late’ follow-up and all isolates.
Amoxicillin/clavulanic acid
P = 0.003
Piperacillin/tazobactam
P = 0.006
Ciprofloxacin
P < 0.001
P = 0.011
P = 0.018
Trimethoprim/sulfamethoxazole
P = 0.009
P = 0.029
A B C D E F 1 2 3 4 5 6 7 8 ALL A B C D E F 1 2 3 4 5 6 7 8 ALL
A B C D E F 1 2 3 4 5 6 7 8 ALL
A B C D E F 1 2 3 4 5 6 7 8 ALL
A B C D E F 1 2 3 4 5 6 7 8 ALL
A B C D E F 1 2 3 4 5 6 7 8 ALL
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Figure 1. Unit-specific benchmark of antibiotic susceptibility. Prevalence of susceptibility to various antibiotics among E. coli recovered from different
hospital sites (A–F: ICUs, 1–8: general wards, ALL: entire hospital). Data are presented as percentage of susceptible isolates+95% confidence interval
(one-sided, 97.5% confidence interval where SR¼ 100%).
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Community-acquired versus nosocomial isolates
Differences between community-acquired and nosocomial
isolates are shown in Table 2. Community-acquired isolates of
E. coli, P. aeruginosa and of coagulase-negative staphylococci
were significantly more often susceptible to various antibiotics
than nosocomial isolates. No significant differences between
nosocomial and community-acquired isolates regarding anti-
biotic susceptibility were observed with S. aureus.
Changes of cumulative antibiograms during
the course of hospitalization
We considered the interval between hospital admission and the
collection of a first specimen and calculated cumulative anti-
biograms of these first isolates for different phases of hospital
stay (Figure 4). A sustained and significant decrease in SRs
during the course of hospitalization could be observed in
coagulase-negative staphylococci tested against gentamicin, oxa-
cillin and rifampicin, but not in E. coli tested against ciprofloxa-
cin, ceftriaxone, amoxicillin/clavulanic acid or piperacillin/
tazobactam. Data on changes of SRs of P. aeruginosa could not
be completely obtained due to low numbers of first isolates in
some of the time periods that were assessed.
Blood, urine or respiratory tract isolates versus
all first isolates
We found significant differences in SRs of organisms recovered
from different anatomical sites (Figure 5). For example,
Escherichia coli
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Figure 2. Comparison of antibiotic susceptibility in ICUs and general
wards. Prevalence of susceptibility to various antibiotics among E. coli and
P. aeruginosa recovered from ICUs and general wards. Data are presented as
percentage of susceptible isolates+95% confidence interval (one-sided,
97.5% confidence interval where SR¼ 100%).
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Figure 3. Difference in antibiotic susceptibility of subsequent isolates.
Prevalence of susceptibility of first, follow-up (identified .2 and 10 days
after first isolate) and all isolates (including repeat isolates) to various
antibiotics among E. coli and P. aeruginosa. Data are presented as
percentage of susceptible isolates+95% confidence interval (one-sided,
97.5% confidence interval where SR¼100%).
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respiratory isolates of E. coli (n ¼ 114) were significantly more
often susceptible to ciprofloxacin than first E. coli isolates
overall (n ¼ 1768; SR 92.11% and 83.83%, respectively,
P, 0.001). The SR to trimethoprim/sulfamethoxazole of E. coli
isolates recovered from blood cultures (n ¼ 94) was significantly
lower than the respective overall SR (SR 50.00% and 70.20%,
respectively, P, 0.001). Furthermore, the proportion of urinary
isolates of P. aeruginosa (n ¼ 107) with susceptibility to imipe-
nem (SR 88.89% and 78.62%, respectively, P ¼ 0.012), mero-
penem (SR 98.02% and 92.51%, respectively, P ¼ 0.049) and
ceftazidime (SR 99.05% and 93.40%, respectively, P ¼ 0.020)
was higher than the corresponding SR of all isolates (n ¼ 567),
whereas isolates from respiratory specimens (n ¼ 190) were
more often resistant to imipenem (SR 64.10% and 78.62%,
respectively, P, 0.001).
Discussion
Information from cumulative antibiogram reports is an important
basis for the selection of empirical antibacterial therapy. Using
stratified analyses of the bacterial susceptibility test results at our
hospital, we found clinically highly relevant dissimilarities of
SRs of important bacterial pathogens across various hospital
departments and between ICUs and general wards. Furthermore,
follow-up isolates (identified between more than 48 h and 10 days
Table 2. Differences in SRs of community-acquired and nosocomial isolates
Mean susceptibility rates (% of isolates) (95% confidence interval)
E. coli P. aeruginosa
community-acquired
(n ¼ 729)
nosocomial
(n ¼ 1017) P value
community-acquired
(n ¼ 219) nosocomial (n ¼ 485) P value
Ampicillin 55.70 (52.05–59.31) 48.47 (45.40–51.55) 0.003 0.45 (0.01–2.51) 0.21 (0.00–1.14) 0.527
Amoxicillin/
clavulanic acid
85.85 (83.12–88.29) 80.60 (78.05–82.97) 0.004 1.36 (0.28–3.93) 0.61 (0.13–1.79) 0.381
Piperacillin/
tazobactam
98.50 (97.33–99.25) 96.50 (95.18–97.54) 0.010 96.36 (92.96–98.42) 94.18 (91.74–96.07) 0.273
First-generation
cephalosporin
82.38 (79.44–85.07) 76.24 (73.52–78.81) 0.002 0.00 (0.00–1.67) 0.41 (0.05–1.47) 1.000
Cefuroxime 92.94 (89.68–95.42) 89.04 (86.01–91.16) 0.071 1.66 (0.34–4.77) 1.63 (0.39–1.97) 1.000
Ceftriaxone 97.94 (96.63–98.84) 97.16 (95.94–98.09) 0.354 10.76 (7.02–15.59) 12.05 (9.32–15.24) 0.707
Ceftazidime 97.60 (96.24–98.57) 96.58 (95.30–97.59) 0.262 94.12 (90.15–96.83) 93.00 (90.40–95.08) 0.631
Cefepime 98.83 (97.04–99.68) 96.72 (94.81–98.08) 0.069 94.05 (89.61–96.99) 93.24 (90.49–95.40) 0.860
Imipenem 100.00 (99.50–100.00) 100.00 (99.64–100.00) 87.95 (82.95–91.90) 76.65 (72.69–80.28) ,0.001
Meropenem 100.00 (99.49–100.00) 100.00 (99.94–100.00) 94.09 (90.11–96.82) 92.17 (89.45–94.37) 0.436
Tobramycin 95.10 (93.27–96.54) 91.80 (89.94–93.40) 0.007 94.14 (90.19–96.85) 95.93 (93.78–97.49) 0.336
Trimethoprim/
sulfamethoxazole
69.65 (66.19–72.95) 67.22 (64.26–70.08) 0.006 6.36 (3.52–10.45) 3.87 (2.35–5.98) 0.176
Ciprofloxacin 94.38 (81.55–86.92) 83.27 (80.84–85.51) 0.566 87.00 (81.86–91.11) 88.17 (85.03–90.85) 0.713
S. aureus coagulase-negative staphylococci
community-acquired
(n ¼ 826)
nosocomial
(n ¼ 836) P value
community-acquired
(n ¼ 372) nosocomial (n ¼ 1261) P value
Amoxicillin/
clavulanic acid
95.73 (94.11–97.01) 97.23 (95.88–98.24) 0.109
Ampicillin 26.08 (23.13–29.21) 23.16 (20.35–26.16) 0.173 30.99 (26.40–35.88) 13.21 (11.42–15.17) ,0.001
Oxacillin 95.64 (94.01–96.93) 97.25 (95.91–98.25) 0.085 73.47 (68.71–77.86) 35.70 (33.09–38.38) ,0.001
Gentamicin 98.91 (97.94–99.50) 98.45 (97.36–99.17) 0.521 87.53 (83.77–90.69) 63.22 (60.56–65.82) ,0.001
Trimethoprim/
sulfamethoxazole
98.67 (97.62–99.33) 98.93 (97.97–99.50) 0.659 75.33 (70.66–79.60) 57.88 (55.26–60.46) ,0.001
Erythromycin 92.19 (90.10–93.96) 91.96 (89.86–93.74) 0.926 60.06 (54.62–65.32) 39.24 (36.47–42.06) ,0.001
Clindamycin 98.36 (97.22–99.13) 98.02 (96.81–98.84) 0.709 83.28 (78.85–87.12) 63.16 (60.38–65.88) ,0.001
Rifampicin 99.75 (99.09–99.97) 99.50 (98.74–99.86) 0.687 96.15 (93.51–97.94) 82.86 (80.61–84.95) ,0.001
Vancomycin/
teicoplanin
100.00 (99.55–100.00) 99.88 (99.34–100.00) 1.000 99.47 (98.09–99.94) 99.22 (98.57–99.63) 1.000
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after the first isolate) of a variety of bacterial species were less sus-
ceptible than first isolates. Likewise, increased duration between
hospital admission and specimen collection was associated with
reduced antimicrobial SRs of some bacterial species. Finally,
isolates from different anatomical sites differed in their SRs.
SRs of bacterial isolates from certain departments may differ
from those of a hospital overall, as previously shown,5 but com-
prehensive unit-specific data are scarce in the literature. We
found striking differences of cumulative antibiograms across
different departments of our hospital. For example, mean SRs of
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Figure 4. Change of antibiotic susceptibility during hospitalization. Changes in the susceptibility to gentamicin, rifampicin and oxacillin in the course of
time after hospital admission among first isolates of coagulase-negative staphylococci (upper panel) and to piperacillin/tazobactam, amoxicillin/clavulanic
acid (middle panel) and ceftriaxone, ciprofloxacin (lower panel) among the first isolates of E. coli. Data are presented as percentage of susceptible isolates
+95% confidence interval (one-sided, 97.5% confidence interval where SR ¼ 100%). *P, 0.05 compared with the SR at days 1–3.
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E. coli to ciprofloxacin ranged between 64.5% and 95.1%, and
those of P. aeruginosa to imipenem and meropenem ranged
from 54.2% to 100% and 80.4% to 100%, respectively.
Furthermore, the results of our study are in agreement with the
findings of previous studies reporting differences in the preva-
lence of antimicrobial resistance among various pathogens
between ICUs, non-ICU units, overall hospital data and between
different ICUs of a single institution.5,12 – 14
Calculations of cumulative antibiograms based on all isolates
tend to overestimate resistance rates due to repeat collection of
strains from patients with complicated clinical course, long hos-
pital stay or with nosocomial infections.15 – 17 Also, specimen-
collection practices, i.e. the frequency of repeat cultures during
patients’ evaluation or the use of surveillance cultures in ICUs,
may influence the SRs. Therefore, guidelines to prepare cumulat-
ive antibiogram reports recommend exclusion of repeat isolates
per episode and emphasize that the ‘first isolate per patient
approach’ has direct relevance to guiding selection of initial
empirical therapy. In contrast, the likelihood of the emergence
of antimicrobial resistance during prolonged or repeat therapy
has to be taken into account during the management of pro-
longed or re-occurring infections.
There is no consensus on the definition of a new infectious
episode following a first one in an individual patient, and there
are no recommended calculation algorithms to detect such
consecutive infectious episodes by analysing microbiological
laboratory data sets.8 However, the ‘first isolate approach’ may
underestimate the resistance rate of complicated infections
because first isolates are often collected early in the course of a
disease. Therefore, the knowledge of the resistance rates of
follow-up isolates may help to empirically adjust antibiotic
therapy in patients whose clinical condition is deteriorating
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Figure 5. Susceptibility of pathogens recovered from different anatomical locations. Prevalence of susceptibility to various antibiotics among P. aeruginosa
and E. coli recovered from different clinical specimens. Data are presented as percentage of susceptible isolates+95% confidence interval (one-sided, 97.5%
confidence interval where SR ¼ 100%).
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despite presumably adequate initial antibiotic coverage. In order
to explore susceptibility data in complicated infections, we
investigated a definition for ‘late’ follow-up isolates (i.e. isolate
identification between more than 48 h and 10 days after the first
one) which is expected to exclude most duplicate isolates. We
found that, in general, mean SRs of ‘late’ follow-up isolates were
lower than the first isolates at our institution. However, we also
observed that resistance rates of ‘late’ follow-up isolates were
similar to the mean of all isolates. Consequently, the easily com-
putable ‘all isolate approach’ may reflect the resistance pattern
of more complicated infection and may serve as important
information in addition to the first isolate antibiograms.
Isolates from nosocomial infections are generally regarded as
less susceptible to antibiotics than community-acquired organisms,
but this is not true for all bacteria or for all hospital sites and
geographic areas.18–20 Nosocomial infection is usually considered
if it begins more than 48 h after hospital admission. Nonetheless,
the point in time during the course of a hospitalization that best
discriminates between more susceptible and more resistant
pathogens remains unclear. To our knowledge, there are no data
available regarding the influence of the time between hospital
admission and specimen collection on cumulative antibiograms.
The effects of antibiotic use on resistance rates in hospitals have
been described previously.21,22 We observed that the mean SRs of
coagulase-negative staphylococci for gentamicin, oxacillin and
rifampicin continuously and significantly decreased in the course
of hospitalization, reflecting the overall selection pressure of anti-
biotic use in an institution. In contrast, no significant or sustained
decrease of susceptibility was detected for E. coli, P. aeruginosa
and S. aureus. Of note, the rate of MRSA at our institution and in
the surrounding region is 3%, which is exceptionally low.
However, as no typing work was done, it remains unclear whether
modifications of the primary pathogen or hospital acquisition of
different strains have a greater influence on these results.
Nevertheless, these findings indicate that a duration of hospitaliz-
ation of more than 48 h before diagnosis of infection and initiation
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Figure 5. Continued.
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of empirical antibacterial therapy may not by itself be a sufficient
criterion for the use of broad-spectrum antibiotics or MRSA-
covering substances.
Whether the anatomical site of specimen collection should be
accounted for in cumulative antibiograms is unclear. Analyses
comparing resistance rates in isolates from different body sites or
blood revealed conflicting results, and only few data on systema-
tic evaluations are available.5,23,24 We found variations in SRs
between specimens of different sources, but these differences
were small for most drug–organism combinations. Nevertheless,
we observed some significant discrepancies such as increased
carbapenem resistance in many respiratory P. aeruginosa
isolates, or an increased resistance rate in uropathogens.
Limitations of the calculation of cumulative antibiograms
have been recognized.5 Because laboratory datasets are based on
the resistance profiles of all isolates sent to the microbiology
laboratory, infection and colonization cannot be distinguished.
A patient’s localization in the hospital at the time of sample
collection may not represent the site where infection was
acquired. Furthermore, even though screening samples for
surveillance purposes are usually marked, some screening
isolates might have been included in our analyses. We cannot
exclude that we found some differences which could be chance
findings due to multiple testing.
In conclusion, we found significant and clinically relevant
discrepancies of mean antimicrobial susceptibility patterns at
our institution depending on the strategy used for data analyses
of cumulative antibiograms. From a practical standpoint, data
reporting including multiple stratification may not appear
feasible at present, but the knowledge of variations of SRs,
specifically within an institution, during different phases of
hospitalization, or of infections at different anatomical sites,
may particularly be beneficial for empirical antibiotic therapy
of complicated infections. In the future, electronic decision
support systems may integrate the results of stratified cumula-
tive antibiograms. We recommend the reporting of unit-specific
cumulative antibiograms, although prospective studies are
needed to evaluate the impact of such reporting on antibiotic
use, treatment outcome and costs. Furthermore, teaching anti-
biotic policies and visualization of the antibiotic selection
pressure within the home institution may be supported by
depicting institution-specific data for selected examples of
frequent bacterial isolates with decreasing SRs during the
course of hospitalization.
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